Document is current
Any future updates will be listed below
-
Authors
Vai, Silvia
Falchetti, Alberto
Corbetta, Sabrina
Bianchi, Maria Luisa
Alberio, Chiara
Carrara, Silvia
Gasperini, Serena
Pretese, Roberta
Parisi, Loredana
Teti, Anna https://orcid.org/0000-0002-5887-4419
Maurizi, Antonio
-
Funding
Funding for this research was provided by:
Agenzia Italiana del Farmaco, Ministero della Salute (AIFA-2016-02364539)
- License Information
-
More Information
Article History
Received: 13 May 2024
Accepted: 3 October 2024
First Online: 25 October 2024
Declarations
:
: Professor Sabrina Corbetta has received research grants from Ascendis Pharma, Theramex, Abiogen Pharma, Gedeon Richter and Savio Pharma Italia, from Italian Ministry of Health, and Fondazione Cariplo to her Institution. All other authors declare no conflict of interest.
: The clinical protocol and the informed consent were approved by the Ethics Committee of all participating Centres (n° 31/2018 for the University of L’Aquila and n° 2017_12_19_05 for Istituto Auxologico Italiano).
: The study involved standard clinical follow-up procedures for patients already taken care of at the participating Centres, with no experimental drugs used. Sera and cells from healthy individuals were collected for cellular studies with their informed consent. The study was conducted in accordance with the Declaration of Helsinki, adhering to the procedures and principles of Good Clinical Practice. No animals were involved in the study.
